Dr. Mark Garofoli discusses a positive stride in advancing patient care and making efforts to ensure that lives within the national opioid crisis are saved and/or improved. One of those positive strides involves the FDA approval of abuse deterrent formulation (ADF) opioid medications, with the aim of preventing the transition from the misuse and/or abuse of prescription opioid medications to illicit drugs. How do these formulations work one might ask?
Did you enjoy this article?
Subscribe to the PAINWeek Newsletter
and get our latest articles and more direct to your inbox